

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILI	NG DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/901,429	07.	/09/2001	David N. Herndon	D6414	7358
7	7590	10/08/2002			
Benjamin Aa			EXAMINER		
ADLER & AS 8011 Candle L		ES	KIM, VICKIE Y		
Houston, TX					,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	,,,,,,			ART UNIT	PAPER NUMBER
				1614	
			DATE MAILED: 10/08/2002 <i>Q</i>		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Office Action Comments	09/901,429	HERNDON, DAVID N.					
Office Action Summary	Examiner	Art Unit					
	Vickie Kim	1614					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period we Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	within the statutory minimum of thirty (30) day ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).					
Status 1) Responsible to communication (a) filed on							
1) Responsive to communication(s) filed on							
· -	s action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4)⊠ Claim(s) <u>1-7, 9-12, 14-20</u> is/are pending in the	application.						
	4a) Of the above claim(s) <u>14-20</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1-7, 9-12</u> is/are rejected.							
7) Claim(s) is/are objected to.	1 <u> </u>						
8) Claim(s) are subject to restriction and/or	election requirement.						
Application Papers	•						
9)☐ The specification is objected to by the Examiner							
10) The drawing(s) filed on is/are: a) accep	ted or b)⊡ objected to by the Exa	miner.					
Applicant may not request that any objection to the	drawing(s) be held in abeyance. So	ee 37 CFR 1.85(a).					
11) The proposed drawing correction filed on	is: a) ☐ approved b) ☐ disappro	ved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
 Certified copies of the priority documents 	1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents	2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)	, 1 , 1 2 2 33 120						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)					

Application/Control Number: 09/901,429

Art Unit: 1614

DETAILED ACTION

Status of Application

- 1. Acknowledgement is made of amendment filed July 02, 2002 in response to the notification of non-compliance. The claims are now amended and entered properly.
- 2. Claims 8 and 13 are canceled. And claims 1-7 and 9-12 are presented for the examination. Non-elected claims 14-20 are withdrawn from the consideration.

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 2. Claims 1-7, 9-12 are rejected under 35 U.S.C. 102(b) as being anticipated by Hernden et al(1994).

Herndon et al teach burn treatment using beta adrenergic blockers such as propranolol is effectively induce the pharmacological effect and treated severely burned patient; see entire text, especially page 1931. 1st paragraph, ,,,,," We have previously shown that nonselective beta-adrenergic receptor blockade with propranolol can be therapeutic in severely burned children and adult....". The βadrenergic antagonists reduce the heart rate from 143+/-15 to 115+/-11(2% -35%). Especially at page 1302, it demonstrates the clinical study wherein the severely burned patients were treated with a pharmacologically effective dose of intravenous propranolol and metoprolol(2mg/kg) to prove therapeutic efficacy without adverse effect. At page 1304,

Application/Control Number: 09/901,429

Art Unit: 1614

in summary, the reference teaches that the β adrenergic antagonists can reduce the heart rate and myocardial oxygen consumptionwithout adversely affecting protein kinetics. Thus the cited reference meet the all the critical elements required by the claims. Thus, all the claimed subject matter is anticipated by the cited reference.

Response to Arguments

3. Applicant's arguments filed July 02, 2002 have been fully considered but they are not persuasive. It is noted that skeletal muscle kinetic improvement is naturally occurring when β adrenergic antagonists are administered to the patient with burns, and thus it is considered to be inherent feature. Since the reference teaches the burn treatment using β adrenergic antagonists(e.g. propranolol), all the claims are anticipated and properly included in this rejection.

Conclusion

- 4. No claim is allowed.
- 5. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any

Application/Control Number: 09/901,429

Art Unit: 1614

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

the advisory action. In no event, however, will the statutory period for reply expire later

than SIX MONTHS from the mailing date of this final action.

6. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Vickie Kim whose telephone number is 703-305-1675.

The examiner can normally be reached on Tuesday-Friday. If attempts to reach the

examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel

can be reached on 703-308-4725. The fax phone numbers for the organization where

this application or proceeding is assigned are 703-746-3165 for regular communications

and 703-746-3165 for After Final communications. Any inquiry of a general nature or

relating to the status of this application or proceeding should be directed to the

receptionist whose telephone number is 703-308-1235.

Vickie Kim,

Patent examiner

October 4, 2002

Art unit 1614

William Jarvis

Primary Patent examiner

Page 4